The pacing, the stages, and the decision to move forward all depend on an individualized clinical assessment that accounts for tolerance, health history, and ongoing feedback
DOI: 10.1038/s41591-026-04476-6 Structure Therapeutics announced the publication via press release on 5 June 2026, framing the open-label extension figures as evidence that weight loss on aleniglipron had not plateaued by week 36 and continued to accrue with longer exposure a pattern also reported in retatrutide's own dose-escalation trials.[2] How Do Aleniglipron and Retatrutide's Trial Data Compare Side by Side
2a) and total mass (Fig
Virta Health offers medical weight-loss support with 1:1 virtual coaching and lifestyle guidance that can help people manage GLP-1 side effects while working toward better health
If you are pregnant, nursing, or taking medication, talk to your doctor first
Overall, only phentermine and its derivatives as well as orlistat were available and used for weight management